Cella David F, Patel Jyoti D
Evanston Northwestern Healthcare, Evanston, IL, USA.
Clin Lung Cancer. 2008 Jul;9(4):206-12. doi: 10.3816/CLC.2008.n.030.
Non-small-cell lung cancer (NSCLC) accounts for > 80% of all lung carcinomas, with the majority of patients presenting with late-stage disease. Selection of an appropriate therapy depends on the stage of disease, with treatment of patients with advanced NSCLC often aimed at palliation of symptoms and improving the well-being of patients. Health-related quality of life (QOL) has been largely ignored as an endpoint in clinical trials for NSCLC, but there is increasing acceptance by clinicians and regulatory authorities that alleviation of symptoms and improved health-related QOL should be carefully considered. This article discusses current approaches to measuring health-related QOL. This discussion is followed by a brief review of some of the current treatment options for patients with NSCLC and their effect on health-related QOL.
非小细胞肺癌（NSCLC）占所有肺癌的80%以上，大多数患者就诊时已处于疾病晚期。选择合适的治疗方法取决于疾病分期，晚期NSCLC患者的治疗通常旨在缓解症状并改善患者的健康状况。在NSCLC的临床试验中，与健康相关的生活质量（QOL）在很大程度上被忽视作为一个终点指标，但临床医生和监管机构越来越认可应仔细考虑缓解症状和改善与健康相关的QOL。本文讨论了目前测量与健康相关QOL的方法。随后简要回顾了NSCLC患者目前的一些治疗选择及其对与健康相关QOL的影响。
